BioSpaceOriginal article
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
Data ReadoutnegativetominersenWVE-003Positive
AI Analysis
Summary
Roche's tominersen, developed with Ionis, has failed in Huntington's disease, which analysts suggest may support the potential of Wave Life Sciences' more selective allele-specific ASO candidate WVE-003 in this indication.
Outcome Details
Roche's Ionis-partnered tominersen failed in Huntington's disease
Importance:6/10
Sentiment:
0.30
Huntington's diseaseantisense oligonucleotideASOallele-specificclinical failurecompetitive landscape
Read the original article
Published by BioSpace on July 13, 2026 6:37 PM